CLINICAL_TRIALS
trial_result
· 2019-09-06
Clinical Trial Update: Evaluate the Immunogenicity of a Novel Glucagon Formulation [Phase 3]
Summary
Phase 3 trial evaluating immunogenicity of a novel glucagon formulation; study completed with results posted in 2019.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Eli Lilly and Company | Conditions: Drug-specific Antibodies, Diabetes Mellitus | Phase 3 | Status: COMPLETED | Results posted: 2019-09-06